


Inborn Errors of Long-Chain Fatty Acid β -Oxidation Link Neural Stem Cell Self-Renewal to Autism

Graphical Abstract



Authors

Zhigang Xie, Albert Jones,
Jude T. Deeney, Seong Kwon Hur,
Vytautas A. Bankaitis

Correspondence

zxie@tamhsc.edu

In Brief

The mechanisms underlying the association between inborn errors of fatty acid metabolism and developmental brain disorders such as autism remain unclear. Xie et al. find that TMLHE, a carnitine biosynthesis enzyme, and carnitine-dependent long-chain fatty acid β -oxidation control the neural stem cell pool during neocortical development by maintaining self-renewing divisions.

Highlights

- TMLHE controls the neural stem cell (NSC) pool in the embryonic mouse neocortex
- CPT1A and fatty acid mobilization from lipid droplets regulate the NSC pool
- TMLHE deficiencies lead to increased symmetric differentiating division of NSCs
- NSC defects under TMLHE deficiencies can be rescued by exogenous carnitine



Inborn Errors of Long-Chain Fatty Acid β -Oxidation Link Neural Stem Cell Self-Renewal to Autism

Zhigang Xie,^{1,*} Albert Jones,² Jude T. Deeney,² Seong Kwon Hur,¹ and Vytas A. Bankaitis¹¹Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, College Station, TX 77843, USA²Department of Medicine, Obesity Research Center, Boston University School of Medicine, Boston, MA 02118, USA*Correspondence: zxie@tamhsc.edu<http://dx.doi.org/10.1016/j.celrep.2016.01.004>This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

SUMMARY

Inborn errors of metabolism (IEMs) occur with high incidence in human populations. Especially prevalent among these are inborn deficiencies in fatty acid β -oxidation (FAO), which are clinically associated with developmental neuropsychiatric disorders, including autism. We now report that neural stem cell (NSC)-autonomous insufficiencies in the activity of TMLHE (an autism risk factor that supports long-chain FAO by catalyzing carnitine biosynthesis), of CPT1A (an enzyme required for long-chain FAO transport into mitochondria), or of fatty acid mobilization from lipid droplets reduced NSC pools in the mouse embryonic neocortex. Lineage tracing experiments demonstrated that reduced flux through the FAO pathway potentiated NSC symmetric differentiating divisions at the expense of self-renewing stem cell division modes. The collective data reveal a key role for FAO in controlling NSC-to-IPC transition in the mammalian embryonic brain and suggest NSC self renewal as a cellular mechanism underlying the association between IEMs and autism.

INTRODUCTION

Inborn errors of metabolism (IEMs) affect approximately 1 in every 800 live births in humans (Pampols, 2010) and are commonly associated with developmental brain syndromes such as autism spectrum disorders and cognitive disabilities. Because those syndromes afflict ~1% and 2%–3% of children, respectively (van Karnebeek and Stockler, 2012; Ghaziuddin and Al-Owain, 2013), these clinical associations argue that understanding the mechanisms underlying these associations will translate into major improvements in treating developmental brain diseases. However, little is known about such underlying mechanisms.

Deficiencies in mitochondrial fatty acid β -oxidation (FAO) are particularly common IEMs. FAO pathways catabolize fatty acids of different chain lengths and represent a major metabolic engine for producing both ATP and reducing power (Houten and Wanders, 2010; Ito and Suda, 2014). The rate-limiting step for

β -oxidation of long-chain fatty acids is their import from the cytoplasm into mitochondria (Figure S1A). This process requires carnitine as an acyl carrier and the action of several enzymes, including carnitine palmitoyltransferase I (CPT1), which catalyzes the rate-limiting reaction in this process. A distinct enzyme, TMLHE trimethyllysine hydroxylase, executes the first step of carnitine biosynthesis (Strijbis et al., 2010). Interestingly, recent studies have shown that *TMLHE* mutations occur with high frequency in human populations (Celestino-Soper et al., 2012; Nava et al., 2012).

Previous studies of mitochondrial FAO largely focused on extracerebral tissues (Houten and Wanders, 2010). However, there is evidence to suggest an association between FAO deficiencies and developmental brain disorders such as autism. Autistic children present altered circulating levels of carnitine or acyl-carnitine (i.e., phenotypes suggestive of deficiencies in long-chain FAO) (Clark-Taylor and Clark-Taylor, 2004; Filipek et al., 2004; Rossignol and Frye, 2012). Reciprocally, children identified as FAO-deficient by genetic screening commonly exhibit signature features of autism, such as developmental delay (Waisbren et al., 2013). Finally, clinical associations of *TMLHE* mutations with increased autism risk are now established (Celestino-Soper et al., 2012; Nava et al., 2012). However, the mechanisms underlying such associations remain unknown.

Given the growing recognition that intermediary metabolism is a central regulator of stem cell homeostasis (Ito and Suda, 2014) and that balanced neural stem cell (NSC) homeostasis is essential for proper brain development (Sun and Hevner, 2014; Taverna et al., 2014), we investigated whether the association between IEMs and developmental brain disorders has an NSC component. Here we report a direct involvement of long-chain FAO in controlling the transition from NSCs to intermediate progenitor cells (IPCs) during brain development in the embryonic mouse. The collective data make a strong case for deranged NSC homeostasis as a significant mechanistic foundation for interpreting the clinical associations between IEMs of fatty acid metabolism and neuropsychiatric disorders.

RESULTS

Reduced TMLHE Expression Causes a Diminished NSC Pool in the Embryonic Neocortex

The identification of *TMLHE* as an autism risk gene motivated us to interrogate whether TMLHE regulates NSC




Figure 1. TMLHE Regulates the Size of the NSC Pool in the Mouse Embryonic Neocortex

Mouse embryos were co-electroporated with an EGFP plasmid and a control or *Tmlhe* shRNA plasmid at E12.5 and sacrificed at E15.5. In rescue groups, a plasmid for expressing shRNA-resistant, wild-type TMLHE (*Tmlhe* shRNA + TMLHE) or shRNA-resistant TMLHE^{D244H} (*Tmlhe* shRNA + D244H) was co-electroporated with *Tmlhe* shRNA and the EGFP plasmid.

(A) Representative confocal images. Areas of the ventricular zone (Pax6⁺ layer) are shown at a higher magnification at the bottom. Scale bars, 50 μ m.

(B) Quantification and statistics.

See also Figures S1 and S2.

by on embryonic day (E) 12.5 murine neocortex by in utero electroporation. Embryos were returned to the uterus, allowed to develop further, and harvested at E15.5. The developmental fates of transfected EGFP⁺ neocortical cells were subsequently followed by in situ immunostaining.

Mouse embryonic NSCs express the nuclear marker Pax6 and produce neurons primarily through IPCs that express the nuclear marker Tbr2 (Englund et al., 2005; Kowalczyk et al., 2009). Therefore, Pax6⁺Tbr2⁻ cells were scored as NSCs and Tbr2⁺ cells as IPCs. Nuclear markers were chosen over cytoplasmic NSC markers (e.g., Nestin) to assign cell identities because these enabled confident scoring of individual cells within the densely packed neocortical sections (Figure S1F). Quantifications based on Pax6 and Tbr2 nuclear marker labeling showed that embryonic neocortices electroporated with either of the *Tmlhe* shRNAs exhibited significant reductions in the

homeostasis during development of the neocortex, the most recently evolved region of the mammalian brain and the one that houses higher brain functions. Both the TMLHE transcript and protein were detected readily in the mouse embryonic neocortex (Figures S1B and S1C). To determine whether and how TMLHE deficiencies affect NSCs, two independent small hairpin RNA (shRNA) plasmids for silencing *Tmlhe* expression were generated (Figures S1D and S1E). Adoption of loss-of-function strategies was motivated by reports that TMLHE mutations associated clinically with autism are expected to ablate, or strongly compromise, the catalytic activity of this enzyme (Celestino-Soper et al., 2012; Nava et al., 2012). *Tmlhe*-directed shRNA plasmids were co-transfected with an EGFP plasmid into an em-

fractional contribution of NSCs to total EGFP⁺ cell populations (Figure 1).

TMLHE Catalytic Activity Is Required for NSC Pool Maintenance

To ensure that the NSC phenotypes observed resulted from specific knockdown of TMLHE rather than off-target effects, a functional complementation experiment was performed. Although an shRNA-resistant wild-type TMLHE rescued the shRNA-induced NSC depletion in the in utero electroporation system, co-expression of the catalytically dead TMLHE^{D244H} did not (Figure 1). This non-functional mutant is the product of the autism-associated TMLHE c.730G→C missense allele that alters D₂₄₄, one of the three key residues of the TMLHE catalytic core (Monfregola

et al., 2005). These data demonstrate that TMLHE catalytic activity is required for maintaining NSC pools in the embryonic neocortex.

TMLHE Deficiencies Preserve Key NSC Features

Several lines of evidence demonstrate that *Tmlhe* shRNA challenges levied specific and biologically interesting NSC deficits. First, *Tmlhe* shRNA-induced reductions in the NSC pool were not due to enhanced cell death or apoptosis in the stem cell population because incidences of EGFP⁺ cells exhibiting either fragmented nuclei or activated Caspase 3 were rare in the control and *Tmlhe* shRNA groups (~0.1%; Figure S1G). Second, no obvious defects in neuronal migration or early neuronal differentiation were induced (Figures S1G and S1H). Third, TMLHE deficiencies left intact other NSC properties critical for self-renewal. Sequential iododeoxyuridine (IdU)/ chlorodeoxyuridine (CldU) injection experiments indicated that TMLHE deficiency did not alter the length of NSC S phase or the cell cycle (Figures S2A–S2C). *Tmlhe* silencing also did not compromise nuclear migration to the ventricular surface of mitotic NSCs (Figures S2D and S2E), indicating that TMLHE deficiency did not impair interkinetic nuclear migration. Similarly, no apparent defects were observed in NSC division cleavage plane (Figures S2F and S2G) or in the apical attachment (Figure S2H).

A bromodeoxyuridine (BrdU) labeling regimen, followed by analysis of actively cycling cells, showed that *Tmlhe* shRNA challenge led to only a modest increase in cells exiting the cell cycle (Figures S2I and S2J). Because the proliferating cell pool consists of both NSCs and IPCs, and given that most IPCs generate postmitotic neurons directly (most NSCs generate neurons via proliferating IPCs), this modest elevation in cell-cycle exit was accounted for by the elevated contribution of IPCs to the proliferating population of *Tmlhe* shRNA-expressing cells.

CPT1 Deficiencies Compromise NSC Pools

To buttress the TMLHE knockdown/rescue results, we tested whether interference with an independent step in the mitochondrial long-chain FAO pathway similarly depleted NSC pools in the embryonic neocortex. To that end, the rate-limiting enzyme for long-chain FAO (CPT1) was targeted for inhibition. Of the three CPT1 isoforms, CPT1A was chosen because *Cpt1a* is expressed in embryonic neocortex, particularly in the ventricular zone (Figure S3A; Genepaint ID: MH509). By contrast, CPT1C does not regulate mitochondrial FAO as a carnitine palmitoyl-transferase (Wolfgang and Lane, 2011), and *Cpt1b* transcripts are not detected in the embryonic mouse brain (Genepaint ID EG2818).

Because mice ablated for *Cpt1a* suffer an early uncharacterized embryonic lethality (Nyman et al., 2005), a *Cpt1a*-directed shRNA plasmid (Figure S3B) was co-electroporated with an EGFP plasmid into the embryonic neocortex at E12.5, and embryos were analyzed at E15.5. Indeed, *Cpt1a* shRNA challenge resulted in a significant decrease in the fractional representation of NSCs in EGFP⁺ cell populations, and this NSC depletion was reversed upon co-expression of an shRNA-resistant *Cpt1a* cDNA (Figures 2A and 2B). Moreover, as observed for TMLHE deficiencies, CPT1A silencing neither enhanced apoptosis nor

did it overtly compromise neuronal migration or differentiation (Figures S3C and S3D).

CPT1A involvement in regulating NSC homeostasis was similarly evident upon NSC intoxication with etomoxir, a small-molecule inhibitor of the enzyme. Because of difficulties in controlling etomoxir exposure in vivo, E12.5 forebrain hemispheres were cultured in media with or without 100 μM etomoxir, a concentration at which etomoxir inhibited FAO activity in neocortical cultures dominated by NSCs (Figures 2C and 2D). The associated phenotypic consequences were thinning of the ventricular zone (Pax6⁺ layer) with accompanying increases in Pax6⁺Tbr2⁺ IPC populations (Figures 2E and 2F), results congruent with the phenotypes evoked by *Tmlhe* and *Cpt1a* knockdown in the intact neocortex. Taken together, the complementary gene silencing and pharmacological intervention data demonstrated that reduced metabolic flux through the long-chain FAO pathway upsets NSC homeostasis.

Reduced Fatty Acid Mobilization from Lipid Droplets Diminishes the NSC Pool

Lipid droplets (LDs) are primary fatty acid depots for mitochondrial FAO (Gross and Silver, 2014), and these structures are found in embryonic NSCs (Bush et al., 1992; Saito et al., 2009). To test whether interfering with fatty acid mobilization from LDs recapitulates the NSC derangements induced by direct compromise of mitochondrial FAO, a dominant-negative interference assay was developed. The experiment was grounded on demonstrations that PLIN1 inhibits LD lipolysis by prohibiting lipase access to LD surfaces. Phosphorylation of PLIN1 by protein kinase A (PKA) at six sites releases this lipolytic block, and PLIN1 mutants that cannot be so phosphorylated are potent dominant-negative inhibitors of LD lipolysis (Figure S3E; Gross and Silver, 2014; Sztalryd and Kimmel, 2014). Co-electroporation of an EGFP plasmid with a vector driving expression of either a mutant PLIN1 with all six PKA phosphorylation sites mutated to alanine (PLIN1-6A) or a PLIN1 with five of the six PKA sites mutated to alanine (PLIN1-5A) evoked significant reductions in NSC pool size (Figures 2G and 2H). Those effects were again evident in the absence of enhanced cell death/apoptosis or overt defects in neuronal migration or neuronal differentiation (Figures S3F and S3G). The data show that withholding LD-derived fatty acids from an otherwise unadulterated mitochondrial FAO pathway elicits NSC homeostatic defects similar to those evoked by direct interference with activities of FAO enzymes.

FAO Regulates the Mitochondrial Redox State

FAO is a major supply for both ATP and reducing power (Houten and Wanders, 2010; Ito and Suda, 2014). To address how diminutions in FAO metabolic flux affect these two NSC parameters, TMLHE and CPT1A expression were knocked down individually by in utero electroporation. Relative ATP levels and redox state were then estimated by taking advantage of imaging readouts afforded by dedicated fluorescent biosensors. To those ends, a plasmid for expressing AT1.03, a cytoplasmic fluorescence resonance energy transfer (FRET)-based ATP biosensor (Imamura et al., 2009), or a mitochondrially targeted AT1.03 (mtAT1.03) was co-electroporated with appropriate shRNA




Figure 2. Targeting CPT1 or Fatty Acid Mobilization Diminished the NSC Pool

(A and B) Silencing *Cpt1a* diminished the NSC pool. Mouse embryos were electroporated at E12.5 and sacrificed at E15.5. In the rescue group (*Cpt1a* shRNA + CPT1A), a plasmid for expressing shRNA-resistant mouse *Cpt1a* cDNA was co-electroporated with *Cpt1a* shRNA and the EGFP plasmid.

(A) Representative confocal images. Areas of the ventricular zone (Pax6⁺ layer) are shown at a higher magnification at the bottom. Scale bars, 50 μ m.

(B) Quantifications.

(C–F) Etomoxir induces increased differentiation of NSCs.

(C) Neocortical cells used for the FAO assay. Dissociated neocortical cells of E11.5 mouse embryos were cultured overnight and then used in a [¹⁴C]-oleate oxidation assay to assess FAO activity. Most cultured cells express the NSC marker Nestin. DAPI labels the nuclei of all cells.

(D) The [¹⁴C]-Oleate oxidation assay confirms that etomoxir inhibits FAO activity in cultured NSCs.

(E and F) Etomoxir potentiated NSC differentiation in organotypic culture of forebrain hemispheres.

(E) Representative images from three independent experiments showing reduced thickness of the ventricular zone (Pax6⁺ layer) in the etomoxir group and an increased fraction of Pax6⁺ cells that co-express Tbr2. The pial surface is outlined by dashed lines. Scale bar, 20 μ m.

(legend continued on next page)

vectors into the embryonic neocortex. Transfected cells exhibiting signature NSC morphologies (bipolar with an apical process contacting the ventricular surface) and locations (soma close to the ventricular surface) were analyzed by ratiometric YFP/CFP FRET imaging. No significant differences in FRET/CFP ratios were discerned between the control and *Tmlhe* shRNA or *Cpt1a* shRNA groups (Figures S3H–S3K), indicating that NSCs maintained substantially normal bulk and mitochondrial ATP levels in the face of TMLHE or CPT1A deficiency.

To monitor the mitochondrial redox status in transfected NSCs, a MitoTimer expression vector was co-electroporated with appropriate shRNA plasmids into an E12.5 embryonic mouse neocortex. MitoTimer is a mitochondrially targeted GFP whose emission wavelengths are sensitive to the redox state of the environment (Laker et al., 2014). Analyses of MitoTimer fluorescence properties were again restricted to transfected cells with morphologies and tissue distributions diagnostic of NSCs. In those cells, MitoTimer localized correctly to mitochondria, and the punctate MitoTimer localization profiles were similar in all experimental groups (Figure S3L). Therefore, neither *Tmlhe* nor *Cpt1a* deficiencies induced significant morphological derangements in the mitochondrial network. However, ratiometric analyses of MitoTimer green/red fluorescence emission spectra showed significant red shifts in NSCs expressing *Tmlhe* shRNA or *Cpt1a* shRNA relative to controls (Figures S3M and S3N), indicating that diminished flux through the FAO pathway resulted in oxidized NSC mitochondrial environments.

TMLHE Regulates NSC Daughter Cell Fate

Embryonic mouse NSCs undergo three exquisitely balanced modes of cell division: a symmetric self-expanding mode that produces two NSC daughters, an asymmetric division that produces one NSC and one differentiated daughter, and a symmetric differentiating mode that produces two differentiated daughters. To assess whether TMLHE deficiency upsets the NSC division program, a two-step electroporation assay was performed to fate daughter pairs derived from the same NSC parent under conditions of reduced TMLHE expression (Figure S4A). In this assay, analyses focused exclusively on vicinal EGFP⁺mCherry⁺ cell pairs because these were inferred to represent daughters arising from one NSC parent.

In the control group, the majority of vicinal EGFP⁺mCherry⁺ cell pairs scored either as NSC/IPC or as NSC/NSC (Figures S4B and S4C), and only a minority scored as IPC/IPC (Figures 3A and 3B). In the *Tmlhe* knockdown group, the incidences of both NSC/IPC and NSC/NSC cell pairs were decreased (Figures S4B and S4C), whereas the fractional contribution of IPC/IPC cell pairs was increased markedly (Figures 3A and 3B). These data suggest that TMLHE maintained NSC pool integrity by inhibiting symmetric differentiating divisions that produce two IPCs.

The effect of TMLHE deficiency on NSC daughter fate was recapitulated in a different assay where Attractene, a nonliposomal transfection reagent, was used to transfect a mouse embryonic neocortex *in vivo*. When an EGFP plasmid was co-injected with Attractene into lateral ventricles of E13.5 mouse embryos, EGFP expression was already apparent 10 hr after injection and became robust by 15 hr. In samples with low transfection efficiencies, EGFP⁺ cells were scattered around the lateral ventricle as isolated single cells or cell pairs that were interpreted to be derived from the division of transfected single cells. Immunostaining analysis 15 hr after transfection revealed that all EGFP⁺ cells (>300 cells examined) were either NSCs or IPCs. Moreover, most of the cell pairs (>90%) were either NSC/IPC or NSC/NSC pairs, whereas the remainder scored as IPC/IPC pairs (Figures S4D and S4E). Because IPCs divide to produce IPCs or postmitotic neurons (but not NSCs), whereas NSCs divide to produce both NSCs and IPCs, these data indicated that the Attractene regimen preferentially transfected NSCs.

To determine the effect of TMLHE deficiency on daughter cell fate during NSC division, a mixture of EGFP plasmid and control or *Tmlhe* shRNA was co-injected with Attractene into the lateral ventricle of E13.5 mouse embryos, and the cell fates of EGFP⁺ cell pairs (but not EGFP⁺ single cells or clones of more than two EGFP⁺ cells) were analyzed after 24 hr when *Tmlhe* shRNA-induced NSC defects were already detectable (Figures S4F and S4G). *Tmlhe* shRNA challenge led to a dramatic increase in the fractional representation of IPC/IPC cell pairs, and this increase was again corrected by co-expression of silencing-resistant, wild-type TMLHE but not silencing-resistant TMLHE^{D244H} (Figures 3C and 3D). Both the fractional representation of NSC/IPC pairs and that of NSC/NSC pairs decreased in the *Tmlhe* shRNA group (Figures S4H and S4I). Although the phenotypes in the Attractene experiments were somewhat milder than those in the two-step electroporation experiments, this difference was expected because it is the likely consequence of less efficient depletion of endogenous TMLHE protein in the Attractene regimen (the interval between shRNA transfection and cell fate analysis was shorter). Therefore, the two-step electroporation and the Attractene transfection data converge to provide compelling evidence that TMLHE deficiencies promote symmetric differentiating NSC divisions that produce two IPCs at the expense of the symmetric NSC/NSC and asymmetric NSC/IPC cell division modes that support stem cell self-renewal.

Exogenous Carnitine Rescues *Tmlhe* shRNA-Induced NSC Defects

Because TMLHE generates a biodeliverable product (carnitine), it was of interest to assess whether depletion of NSCs from the embryonic neocortex in the face of TMLHE deficiencies could

(F) Quantifications. The percentage of Pax6⁺ cells that co-express Tbr2 was increased significantly in the etomoxir group.

(G and H) Blocking fatty acid mobilization from lipid droplets by overexpressing dominant-negative mutants of PLIN1 diminished the NSC pool. Mouse embryos were electroporated at E12.5 and sacrificed at E15.5.

(G) Representative confocal images. Areas of the ventricular zone (Pax6⁺ layer) are shown at a higher magnification at the bottom. Scale bars, 50 μ m.

(H) Quantification and statistics.

See also Figure S3.




Figure 3. TMLHE Inhibits Symmetric NSC Division that Produces Two IPCs

(A and B) Analysis of NSC division by two-step electroporation assay.

(A) Representative images showing vicinal EGFP⁺mCherry⁺ cell pairs of NSC/NSC, NSC/IPC, and IPC/IPC. White and yellow arrows indicate NSCs (Pax6⁺Tbr2⁺) and IPCs (Tbr2⁺), respectively. Scale bars, 20 μ m.

(B) Quantification and statistics.

(C and D) Analysis of NSC division using Attractene-mediated transfection.

(C) Representative images showing vicinal EGFP⁺ cell pairs of NSC/NSC, NSC/IPC, and IPC/IPC. White and yellow arrows indicate NSCs and IPCs, respectively. Scale bars, 20 μ m.

(D) Quantification and statistics.

See also Figure S4.

be remediated by providing carnitine to the tissue. Control or *Tmlhe* shRNAs were co-electroporated with an EGFP plasmid into a mouse embryonic neocortex at E12.5, and electroporated embryos were allowed to develop in utero for a further 24 hr before being sacrificed. Forebrain hemispheres were then dissected and incubated in physiological glucose media with or without carnitine supplementation for 18 hr (Figure 4A). Under those conditions, *Tmlhe* shRNA induced a 2-fold decrease in the fractional representation of NSCs in EGFP⁺ cell populations, and this reduction was rescued by inclusion of carnitine in the incubation medium (Figures 4B and 4C). Therefore, derangements in NSC pools caused by TMLHE deficiencies are carnitine-remedial. Although the NSC pool was not recovered completely, we noted that *Tmlhe* shRNA had already reduced the NSC pool size by 24 hr after electroporation (i.e., prior to carnitine supplementation; Figures S4F and S4G). Further analyses revealed that, although carnitine supplementation significantly enlarged the NSC pool in the *Tmlhe* shRNA group, it did not expand the NSC pool in the control group (Figure 4C). This result indicated

that exogenous carnitine modulates NSC pools only when endogenous carnitine biosynthesis is compromised.

DISCUSSION

Here, we demonstrate a critical requirement for long-chain FAO in maintaining NSC homeostasis in the mammalian embryonic neocortex. The key evidence includes gene silencing and chemical inhibition approaches that interfere with distinct enzymatic reactions in the mitochondrial FAO pathway and dominant-negative approaches that restrict substrate entry into a biochemically uncompromised mitochondrial FAO pathway. These results demonstrate that reduced flux through this catabolic pathway directly disturbs NSC homeostasis by inappropriately enhancing the transition of NSCs to IPC lineages. Our findings offer a mechanistic framework for interpreting the associations between FAO deficiencies and developmental brain disorders and provide a biochemical basis to explain why TMLHE scores as an autism-linked gene.




Figure 4. Exogenous Carnitine Largely Rescues *Tmlhe* shRNA-Induced NSC Defects

(A) Experimental procedures.
(B) Representative confocal images. Scale bars, 20 μ m.
(C) Quantification and statistics.

Lineage tracing experiments demonstrate that an active FAO pathway supports NSC pool maintenance in the embryonic neocortex by dampening the frequency of symmetric differentiating cell divisions that give rise to lineage-restricted cells (IPCs) at the expense of NSC self-renewal. The relevance of this activity to autism is underscored by growing evidence showing that established autism-linked genes or pathways are key regulators of the NSC-to-IPC transition (Mutch et al., 2010; Saffary and Xie, 2011; Bian et al., 2013; Lv et al., 2013; Krumm et al., 2014; O’Roak et al., 2014). Our data further show that flux through the mitochondrial FAO pathway controls a metabolic trigger that regulates daughter cell fate during NSC division. The nature of this trigger remains unclear. Although in vitro data suggest that FAO maintains energy levels in adult subventricular zone (SVZ) neural stem and/or progenitor cells (Stoll et al., 2015), our in vivo experiments measured no significant derangements in bulk or mitochondrial ATP pools in FAO-deficient NSCs. However, because ATP levels are highly buffered in cells, we cannot discount the possibility that mitochondrial FAO insufficiencies are accompanied by compensatory metabolic adaptations that marshal other metabolic resources in support of bulk intracellular ATP. Such compensatory metabolic adaptations might be accompanied by wider pleiotropic effects that could influence daughter cell fate during NSC division.

With regard to redox status, enhanced oxidative environments were registered in NSC mitochondria with diminished FAO activity, suggesting that enhanced oxidative microenvironments impair NSC self-renewal in the mouse embryonic neocortex. Although reactive oxygen species are reported to regulate NSC self-renewal in the adult mouse brain (Le Belle et al., 2011), in that case, oxidative stress promoted NSC self-renewal

rather than diminishing that capacity; i.e., the conclusion we arrive at here. Perhaps NSC self-renewal is regulated differentially as a function of magnitude of the oxidative stimulus. Alternatively, embryonic NSCs may fundamentally differ from adult brain NSCs in their metabolic wiring.

Why has a direct role for FAO in NSCs and brain development been largely ignored? First, classical studies of brain energy metabolism focused on neurons, glial cells, or the brain at the organ level (Bélanger et al., 2011). Because NSCs constitute only a small fraction of brain cells, NSC metabolic activity does not contribute significantly to the bulk-averaging measurements that define many analyses. Second, characterization of NSC defects in animal models of FAO deficiencies is confounded by broader physiological consequences of these metabolic defects. For instance, mice ablated for *Cpt1a* suffer an early embryonic lethality presumed to reflect systemic metabolic failures (Nyman et al., 2005). Third, previous studies of NSC metabolism relied on dissociated NSC cultures. Those strategies, although convenient, ignore niche parameters that regulate NSC self-renewal. By contrast, the experimental paradigms used here imposed TMLHE and CPT1A insufficiencies acutely, in situ, and in a manner restricted to defined subsets of cells within the embryonic neocortex. Such manipulation of NSCs, in an authentic physiological context, exposed the critical role played by long-chain FAO in NSC self-renewal. Although our analyses were restricted to mitochondrial β -oxidation of long-chain fatty acids, inherited deficiencies in medium- and short-chain FAO pathways are also recognized to predispose affected patients to developmental challenges (Waisbren et al., 2013). Our findings now raise the possibility that those diseases also reflect derangements in NSC homeostatic control.

Finally, linkage of NSC homeostatic mechanisms with IEMs of developmental brain disorders has clinical implications. *TMLHE* deficiencies represent the most frequent IEMs (Pampols, 2010; Celestino-Soper et al., 2012; Nava et al., 2012) and are associated with an increased autism risk. The carnitine rescue experiment suggests actionable prophylactic measures for minimizing developmental brain deficits associated with *TMLHE* deficiencies. We forecast that elevation of the fetal carnitine supply will prove to be an effective strategy for alleviating developmental brain deficits associated with inborn *TMLHE* mutations. The commercial availability of carnitine as a nutritional supplement notwithstanding, this compound is not on the list of dietary supplements recommended by the Food and Drug Administration (FDA) for pregnant women. We suggest that genetic screening of prospective parents for *TMLHE* mutations, coupled with inclusion of carnitine as a dietary supplement upon initial diagnosis of pregnancy, promises mental health benefits for newborns otherwise at significant risk for developmental brain disorders.

EXPERIMENTAL PROCEDURES

Detailed experimental procedures are provided in the [Supplemental Experimental Procedures](#).

Animals and In Utero Electroporation

Swiss Webster female mice were purchased from Taconic, Charles River Laboratories, or Harlan Laboratories. Mice were handled in accordance with NIH and institutional guidelines regarding the care and use of animals. In utero electroporation was performed as described previously (Saffary and Xie, 2011).

Tissue Preparation and Immunostaining

Electroporated mouse embryos were sacrificed by decapitation. Forebrain hemispheres were fixed in 2% paraformaldehyde (prepared in PBS) for 20–30 min. Cryosections (30–40 μ m) were prepared from the hemispheres and used for immunostaining.

Statistical Analysis

Statistical analysis was performed using GraphPad Prism software.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures and four figures and can be found with this article online at <http://dx.doi.org/10.1016/j.celrep.2016.01.004>.

AUTHOR CONTRIBUTIONS

Z.X. conceptualized, designed, and performed the research; analyzed the data; and wrote the manuscript. V.A.B. designed the research, analyzed the data, and edited the manuscript. A.J. and J.T.D. designed, performed, and analyzed FAO metabolic flux measurements. S.K.H. contributed to in utero electroporation assays.

ACKNOWLEDGMENTS

This work was supported by the Robert A. Welch Foundation (Award BE0017 to V.A.B.) and grants from the NIH (1R21HD069857 to Z.X. and RO1GM112591 to V.A.B.). J.T.D. was supported by NIH Grant R01DK035914. We thank C. Gonzales for technical assistance; F.B. Gertler for providing the pCAX-EGFP and pCAX-mCherry plasmids; and L.H. Tsai, I. Delalle, and R.B. Mouneimne for microscopy support. The Pax6 antibody

developed by A. Kawakami was obtained from the Developmental Studies Hybridoma Bank, developed under the auspices of the National Institute of Child Health and Human Development, and maintained by the Department of Biology, University of Iowa, Iowa City, IA.

Received: June 2, 2015

Revised: October 23, 2015

Accepted: December 28, 2015

Published: January 28, 2016

REFERENCES

- Bélangier, M., Allaman, I., and Magistretti, P.J. (2011). Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. *Cell Metab.* *14*, 724–738.
- Bian, S., Hong, J., Li, Q., Schebelle, L., Pollock, A., Knauss, J.L., Garg, V., and Sun, T. (2013). MicroRNA cluster miR-17-92 regulates neural stem cell expansion and transition to intermediate progenitors in the developing mouse neocortex. *Cell Rep.* *3*, 1398–1406.
- Bush, K.T., Lee, H., and Nagele, R.G. (1992). Lipid droplets of neuroepithelial cells are a major calcium storage site during neural tube formation in chick and mouse embryos. *Experientia* *48*, 516–519.
- Celestino-Soper, P.B., Violante, S., Crawford, E.L., Luo, R., Lionel, A.C., Delaby, E., Cai, G., Sadikovic, B., Lee, K., Lo, C., et al. (2012). A common X-linked inborn error of carnitine biosynthesis may be a risk factor for nondysmorphic autism. *Proc. Natl. Acad. Sci. USA* *109*, 7974–7981.
- Clark-Taylor, T., and Clark-Taylor, B.E. (2004). Is autism a disorder of fatty acid metabolism? Possible dysfunction of mitochondrial beta-oxidation by long chain acyl-CoA dehydrogenase. *Med. Hypotheses* *62*, 970–975.
- Englund, C., Fink, A., Lau, C., Pham, D., Daza, R.A., Bulfone, A., Kowalczyk, T., and Hevner, R.F. (2005). Pax6, Tbr2, and Tbr1 are expressed sequentially by radial glia, intermediate progenitor cells, and postmitotic neurons in developing neocortex. *J. Neurosci.* *25*, 247–251.
- Filipek, P.A., Juranek, J., Nguyen, M.T., Cummings, C., and Gargus, J.J. (2004). Relative carnitine deficiency in autism. *J. Autism Dev. Disord.* *34*, 615–623.
- Ghazizuddin, M., and Al-Owain, M. (2013). Autism spectrum disorders and inborn errors of metabolism: an update. *Pediatr. Neurol.* *49*, 232–236.
- Gross, D.A., and Silver, D.L. (2014). Cytosolic lipid droplets: from mechanisms of fat storage to disease. *Crit. Rev. Biochem. Mol. Biol.* *49*, 304–326.
- Houten, S.M., and Wanders, R.J. (2010). A general introduction to the biochemistry of mitochondrial fatty acid β -oxidation. *J. Inher. Metab. Dis.* *33*, 469–477.
- Imamura, H., Nhat, K.P., Togawa, H., Saito, K., Iino, R., Kato-Yamada, Y., Nagai, T., and Noji, H. (2009). Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators. *Proc. Natl. Acad. Sci. USA* *106*, 15651–15656.
- Ito, K., and Suda, T. (2014). Metabolic requirements for the maintenance of self-renewing stem cells. *Nat. Rev. Mol. Cell Biol.* *15*, 243–256.
- Kowalczyk, T., Pontius, A., Englund, C., Daza, R.A., Bedogni, F., Hodge, R., Attardo, A., Bell, C., Huttner, W.B., and Hevner, R.F. (2009). Intermediate neuronal progenitors (basal progenitors) produce pyramidal-projection neurons for all layers of cerebral cortex. *Cereb. Cortex* *19*, 2439–2450.
- Krumm, N., O’Roak, B.J., Shendure, J., and Eichler, E.E. (2014). A de novo convergence of autism genetics and molecular neuroscience. *Trends Neurosci.* *37*, 95–105.
- Laker, R.C., Xu, P., Ryall, K.A., Sujkowski, A., Kenwood, B.M., Chain, K.H., Zhang, M., Royal, M.A., Hoehn, K.L., Driscoll, M., et al. (2014). A novel MitoTimer reporter gene for mitochondrial content, structure, stress, and damage in vivo. *J. Biol. Chem.* *289*, 12005–12015.
- Le Belle, J.E., Orozco, N.M., Paucar, A.A., Saxe, J.P., Mottahedeh, J., Pyle, A.D., Wu, H., and Kornblum, H.I. (2011). Proliferative neural stem cells have high endogenous ROS levels that regulate self-renewal and neurogenesis in a PI3K/Akt-dependant manner. *Cell Stem Cell* *8*, 59–71.

- Lv, J.W., Cheng, T.L., Qiu, Z.L., and Zhou, W.H. (2013). Role of the PTEN signaling pathway in autism spectrum disorder. *Neurosci. Bull.* *29*, 773–778.
- Monfregola, J., Cevenini, A., Terracciano, A., van Vlies, N., Arbucci, S., Wanders, R.J., D'Urso, M., Vaz, F.M., and Ursini, M.V. (2005). Functional analysis of TMLH variants and definition of domains required for catalytic activity and mitochondrial targeting. *J. Cell. Physiol.* *204*, 839–847.
- Mutch, C.A., Schulte, J.D., Olson, E., and Chenn, A. (2010). Beta-catenin signaling negatively regulates intermediate progenitor population numbers in the developing cortex. *PLoS ONE* *5*, e12376.
- Nava, C., Lamari, F., Héron, D., Mignot, C., Rastetter, A., Keren, B., Cohen, D., Faudet, A., Bouteiller, D., Gilleron, M., et al. (2012). Analysis of the chromosome X exome in patients with autism spectrum disorders identified novel candidate genes, including TMLHE. *Transl. Psychiatry* *2*, e179.
- Nyman, L.R., Cox, K.B., Hoppel, C.L., Kerner, J., Barnoski, B.L., Hamm, D.A., Tian, L., Schoeb, T.R., and Wood, P.A. (2005). Homozygous carnitine palmitoyltransferase 1a (liver isoform) deficiency is lethal in the mouse. *Mol. Genet. Metab.* *86*, 179–187.
- O'Roak, B.J., Stessman, H.A., Boyle, E.A., Witherspoon, K.T., Martin, B., Lee, C., Vives, L., Baker, C., Hiatt, J.B., Nickerson, D.A., et al. (2014). Recurrent de novo mutations implicate novel genes underlying simplex autism risk. *Nat. Commun.* *5*, 5595.
- Pampols, T. (2010). Inherited metabolic rare disease. *Adv. Exp. Med. Biol.* *686*, 397–431.
- Rossignol, D.A., and Frye, R.E. (2012). Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. *Mol. Psychiatry* *17*, 290–314.
- Saffary, R., and Xie, Z. (2011). FMRP regulates the transition from radial glial cells to intermediate progenitor cells during neocortical development. *J. Neurosci.* *31*, 1427–1439.
- Saito, K., Dubreuil, V., Arai, Y., Wilsch-Bräuninger, M., Schwudke, D., Saher, G., Miyata, T., Breier, G., Thiele, C., Shevchenko, A., et al. (2009). Ablation of cholesterol biosynthesis in neural stem cells increases their VEGF expression and angiogenesis but causes neuron apoptosis. *Proc. Natl. Acad. Sci. USA* *106*, 8350–8355.
- Stoll, E.A., Makin, R., Sweet, I.R., Trevelyan, A.J., Miwa, S., Horner, P.J., and Turnbull, D.M. (2015). Neural stem cells in the adult subventricular zone oxidize fatty acids to produce energy and support neurogenic activity. *Stem Cells* *33*, 2306–2319.
- Strijbis, K., Vaz, F.M., and Distel, B. (2010). Enzymology of the carnitine biosynthesis pathway. *IUBMB Life* *62*, 357–362.
- Sun, T., and Hevner, R.F. (2014). Growth and folding of the mammalian cerebral cortex: from molecules to malformations. *Nat. Rev. Neurosci.* *15*, 217–232.
- Sztalryd, C., and Kimmel, A.R. (2014). Perilipins: lipid droplet coat proteins adapted for tissue-specific energy storage and utilization, and lipid cytoprotection. *Biochimie* *96*, 96–101.
- Taverna, E., Götz, M., and Huttner, W.B. (2014). The cell biology of neurogenesis: toward an understanding of the development and evolution of the neocortex. *Annu. Rev. Cell Dev. Biol.* *30*, 465–502.
- van Karnebeek, C.D., and Stockler, S. (2012). Treatable inborn errors of metabolism causing intellectual disability: a systematic literature review. *Mol. Genet. Metab.* *105*, 368–381.
- Waisbren, S.E., Landau, Y., Wilson, J., and Vockley, J. (2013). Neuropsychological outcomes in fatty acid oxidation disorders: 85 cases detected by newborn screening. *Dev. Disabil. Res. Rev.* *17*, 260–268.
- Wolfgang, M.J., and Lane, M.D. (2011). Hypothalamic malonyl-CoA and CPT1c in the treatment of obesity. *FEBS J.* *278*, 552–558.